DalCor Pharmaceuticals

DalCor Pharmaceuticals is a clinical-stage biopharmaceutical company based in Montreal, Quebec, Canada.

Founded in 2015, the company focuses on developing precision pharmacogenetic medicine to address cardiovascular diseases. DalCor aims to improve patient outcomes by targeting specific genetic profiles, particularly the ADCY9 AA genotype, to deliver tailored therapies. The company's lead product, Dalcetrapib, is a small-molecule therapeutic designed to reduce the risk of recurrent myocardial infarction and other cardiovascular events in patients with the identified genetic marker. Dalcetrapib is currently undergoing evaluation in the Dal-GenE-2 Phase 3 trial, which is supported by a partnership with Roche for companion diagnostics. DalCor also has a related program, Dal-GenE, aimed at reducing cardiovascular events in genetically distinct patient subsets. With a global presence that includes offices in the USA, Switzerland, and the UK, DalCor is committed to advancing cardiovascular care through rigorous clinical trials and innovative genetic research.